{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T17:12:22Z","timestamp":1783703542281,"version":"3.55.0"},"reference-count":70,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T00:00:00Z","timestamp":1669593600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Brain A\u03b2 deposition is a key early event in the pathogenesis of Alzheimer\u00b4s disease (AD), but the long presymptomatic phase and poor correlation between A\u03b2 deposition and clinical symptoms remain puzzling. To elucidate the dependency of downstream pathologies on A\u03b2, we analyzed the trajectories of cerebral A\u03b2 accumulation, A\u03b2 seeding activity, and neurofilament light chain (NfL) in the CSF (a biomarker of neurodegeneration) in A\u03b2-precursor protein transgenic mice. We find that A\u03b2 deposition increases linearly until it reaches an apparent plateau at a late age, while A\u03b2 seeding activity increases more rapidly and reaches a plateau earlier, coinciding with the onset of a robust increase of CSF NfL. Short-term inhibition of A\u03b2 generation in amyloid-laden mice reduced A\u03b2 deposition and associated glial changes, but failed to reduce A\u03b2 seeding activity, and CSF NfL continued to increase although at a slower pace. When short-term or long-term inhibition of A\u03b2 generation was started at pre-amyloid stages, CSF NfL did not increase despite some A\u03b2 deposition, microglial activation, and robust brain A\u03b2 seeding activity. A dissociation of A\u03b2 load and CSF NfL trajectories\u00a0was also found in familial AD, consistent with the view that A\u03b2 aggregation is not kinetically coupled to neurotoxicity. Rather, neurodegeneration starts when A\u03b2 seeding activity is saturated and before A\u03b2 deposition reaches critical (half-maximal) levels, a phenomenon reminiscent of the two pathogenic phases in prion disease.<\/jats:p>","DOI":"10.1038\/s41467-022-34538-5","type":"journal-article","created":{"date-parts":[[2022,11,28]],"date-time":"2022-11-28T15:11:51Z","timestamp":1669648311000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Experimental evidence for temporal uncoupling of brain A\u03b2 deposition and neurodegenerative sequelae"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5038-0465","authenticated-orcid":false,"given":"Christine","family":"Rother","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Uhlmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3414-307X","authenticated-orcid":false,"given":"Stephan A.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliane","family":"Schelle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelos","family":"Skodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Oberm\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"H\u00e4sler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius","family":"Lambert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Baumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carina","family":"Bergmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Salvadori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1629-2928","authenticated-orcid":false,"given":"Maarten","family":"Loos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irena","family":"Brzak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derya","family":"Shimshek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulf","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"Dominantly Inherited Alzheimer Network","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9166-3261","authenticated-orcid":false,"given":"Lary C.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie A.","family":"Schultz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7792-1698","authenticated-orcid":false,"given":"Jasmeer P.","family":"Chhatwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan A.","family":"Kaeser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2211-2575","authenticated-orcid":false,"given":"Stefan F.","family":"Lichtenthaler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthias","family":"Staufenbiel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9045-1072","authenticated-orcid":false,"given":"Mathias","family":"Jucker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,28]]},"reference":[{"key":"34538_CR1","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1038\/s41593-018-0238-6","volume":"21","author":"M Jucker","year":"2018","unstructured":"Jucker, M. & Walker, L. C. Propagation and spread of pathogenic protein assemblies in neurodegenerative diseases. Nat. Neurosci. 21, 1341\u20131349 (2018).","journal-title":"Nat. Neurosci."},{"key":"34538_CR2","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1038\/s41582-021-00545-1","volume":"17","author":"E McDade","year":"2021","unstructured":"McDade, E. et al. The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nat. Rev. Neurol. 17, 703\u2013714 (2021).","journal-title":"Nat. Rev. Neurol."},{"key":"34538_CR3","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1212\/WNL.0000000000006277","volume":"91","author":"E McDade","year":"2018","unstructured":"McDade, E. et al. Longitudinal cognitive and biomarker changes in dominantly inherited Alzheimer disease. Neurology 91, 1295\u20131306 (2018).","journal-title":"Neurology"},{"key":"34538_CR4","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1038\/nrneurol.2018.9","volume":"14","author":"VL Villemagne","year":"2018","unstructured":"Villemagne, V. L., Dor\u00e9, V., Burnham, S. C., Masters, C. L. & Rowe, C. C. Imaging tau and amyloid-beta proteinopathies in Alzheimer disease and other conditions. Nat. Rev. Neurol. 14, 225\u2013236 (2018).","journal-title":"Nat. Rev. Neurol."},{"key":"34538_CR5","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","volume":"297","author":"J Hardy","year":"2002","unstructured":"Hardy, J. & Selkoe, D. The amyloid hypothesis of Alzheimer\u2019s disease: progress and problems on the road to therapeutics. Science 297, 353\u2013356 (2002).","journal-title":"Science"},{"key":"34538_CR6","doi-asserted-by":"publisher","first-page":"698","DOI":"10.1038\/nrd3505","volume":"10","author":"E Karran","year":"2011","unstructured":"Karran, E., Mercken, M. & Strooper, B. De. The amyloid cascade hypothesis for Alzheimer\u2019s disease: an appraisal for the development of therapeutics. Nat. Rev. Drug Discov. 10, 698\u2013712 (2011).","journal-title":"Nat. Rev. Drug Discov."},{"key":"34538_CR7","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/j.jalz.2012.07.002","volume":"9","author":"H Zetterberg","year":"2013","unstructured":"Zetterberg, H. & Blennow, K. Biomarker evidence for uncoupling of amyloid build-up and toxicity in Alzheimer\u2019s disease. Alzheimers Dement. 9, 459\u2013462 (2013).","journal-title":"Alzheimers Dement."},{"key":"34538_CR8","doi-asserted-by":"publisher","first-page":"1250","DOI":"10.1126\/science.aau0437","volume":"362","author":"T Golde","year":"2018","unstructured":"Golde, T., DeKosky, S. & Galasko, D. Alzheimer\u2019s disease: the right drug, the right time. Science 362, 1250\u20131251 (2018).","journal-title":"Science"},{"key":"34538_CR9","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1038\/547153a","volume":"547","author":"E McDade","year":"2017","unstructured":"McDade, E. & Bateman, R. J. Stop Alzheimer\u2019s before it starts. Nature 547, 153\u2013155 (2017).","journal-title":"Nature"},{"key":"34538_CR10","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.1212\/WNL.0000000000011524","volume":"96","author":"W Jagust","year":"2021","unstructured":"Jagust, W. & Landau, S. Temporal dynamics of \u03b2-amyloid accumulation in aging and Alzheimer disease. Neurology 96, 1347\u20131357 (2021).","journal-title":"Neurology"},{"key":"34538_CR11","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.neuron.2016.05.018","volume":"91","author":"M Bacioglu","year":"2016","unstructured":"Bacioglu, M. et al. Neurofilament light chain in blood and CSF as marker of disease progression in mouse models and in neurodegenerative diseases. Neuron 91, 56\u201366 (2016).","journal-title":"Neuron"},{"key":"34538_CR12","doi-asserted-by":"publisher","first-page":"1975","DOI":"10.1093\/brain\/awaa098","volume":"143","author":"A Gafson","year":"2020","unstructured":"Gafson, A. et al. Neurofilaments: neurobiological foundations for biomarker applications. Brain 143, 1975\u20131998 (2020).","journal-title":"Brain"},{"key":"34538_CR13","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.15252\/embr.201744067","volume":"18","author":"L Ye","year":"2017","unstructured":"Ye, L. et al. A\u03b2 seeding potency peaks in the early stages of cerebral \u03b2-amyloidosis. EMBO Rep. 18, 1536\u20131544 (2017).","journal-title":"EMBO Rep."},{"key":"34538_CR14","doi-asserted-by":"publisher","first-page":"3435","DOI":"10.1111\/bph.14582","volume":"176","author":"U Neumann","year":"2019","unstructured":"Neumann, U., Machauer, R. & Shimshek, D. R. The \u03b2-secretase (BACE) inhibitor NB-360 in preclinical models: From amyloid-\u03b2 reduction to downstream disease-relevant effects. Br. J. Pharmacol. 176, 3435\u20133446 (2019).","journal-title":"Br. J. Pharmacol."},{"key":"34538_CR15","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1016\/j.jalz.2016.09.005","volume":"13","author":"J Schelle","year":"2017","unstructured":"Schelle, J. et al. Prevention of tau increase in cerebrospinal fluid of APP transgenic mice suggests downstream effect of BACE1 inhibition. Alzheimer\u2019s Dement 13, 701\u2013709 (2017).","journal-title":"Alzheimer\u2019s Dement"},{"key":"34538_CR16","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1002\/ana.25562","volume":"86","author":"J Schelle","year":"2019","unstructured":"Schelle, J. et al. Early A\u03b2 reduction prevents progression of cerebral amyloid angiopathy. Ann. Neurol. 86, 561\u2013571 (2019).","journal-title":"Ann. Neurol."},{"key":"34538_CR17","doi-asserted-by":"publisher","first-page":"12781","DOI":"10.1111\/nan.12781","volume":"48","author":"M Querol-Vilaseca","year":"2022","unstructured":"Querol-Vilaseca, M. et al. Neuropathology of a patient with Alzheimer disease treated with low doses of verubecestat. Neuropathol. Appl. Neurobiol. 48, 12781\u201312787 (2022).","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"34538_CR18","doi-asserted-by":"publisher","first-page":"33304","DOI":"10.1074\/jbc.M112.395608","volume":"287","author":"J Bien","year":"2012","unstructured":"Bien, J. et al. The metalloprotease meprin \u03b2 generates amino terminal-truncated amyloid \u03b2 peptide species. J. Biol. Chem. 287, 33304\u201333313 (2012).","journal-title":"J. Biol. Chem."},{"key":"34538_CR19","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1038\/sj.embor.7400784","volume":"7","author":"R Radde","year":"2006","unstructured":"Radde, R. et al. Abeta42-driven cerebral amyloidosis in transgenic mice reveals early and robust pathology. EMBO Rep. 7, 940\u2013946 (2006).","journal-title":"EMBO Rep."},{"key":"34538_CR20","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.cell.2019.09.001","volume":"179","author":"JM Long","year":"2019","unstructured":"Long, J. M. & Holtzman, D. M. Alzheimer disease: an update on pathobiology and treatment strategies. Cell 179, 312\u2013339 (2019).","journal-title":"Cell"},{"key":"34538_CR21","doi-asserted-by":"publisher","first-page":"801","DOI":"10.1016\/j.neuron.2020.09.029","volume":"108","author":"J Lewcock","year":"2020","unstructured":"Lewcock, J. et al. Emerging microglia biology defines novel therapeutic approaches for Alzheimer\u2019s disease. Neuron 108, 801\u2013821 (2020).","journal-title":"Neuron"},{"key":"34538_CR22","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1038\/s41591-021-01456-w","volume":"27","author":"T Pascoal","year":"2021","unstructured":"Pascoal, T. et al. Microglial activation and tau propagate jointly across Braak stages. Nat. Med. 27, 1592\u20131599 (2021).","journal-title":"Nat. Med."},{"key":"34538_CR23","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia, L. F. et al. Changes in amyloid-\u03b2 and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5, 194re2 (2013).","journal-title":"Sci. Transl. Med."},{"key":"34538_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1038\/s41591-020-0781-z","volume":"26","author":"NR Barth\u00e9lemy","year":"2020","unstructured":"Barth\u00e9lemy, N. R. et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer\u2019s disease. Nat. Med. 26, 398 (2020).","journal-title":"Nat. Med."},{"key":"34538_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/s00401-021-02400-5","volume":"143","author":"SA Kaeser","year":"2022","unstructured":"Kaeser, S. A. et al. CSF p-tau increase in response to A\u03b2-type and Danish-type cerebral amyloidosis and in the absence of neurofibrillary tangles. Acta Neuropathol. 143, 287\u2013290 (2022).","journal-title":"Acta Neuropathol."},{"key":"34538_CR26","doi-asserted-by":"crossref","unstructured":"Kumar, A. et al. \u03b2-amyloid\u2013dependent and \u2013independent genetic pathways regulating CSF tau biomarkers in Alzheimer disease. Neurology 99, e476-e487 (2022).","DOI":"10.1212\/WNL.0000000000200605"},{"key":"34538_CR27","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1038\/s41591-018-0304-3","volume":"25","author":"O Preische","year":"2019","unstructured":"Preische, O. et al. Serum neurofilament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer\u2019s disease. Nat. Med. 25, 277\u2013283 (2019).","journal-title":"Nat. Med."},{"key":"34538_CR28","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1016\/S1474-4422(21)00375-6","volume":"21","author":"JP Chhatwal","year":"2022","unstructured":"Chhatwal, J. P. et al. Variant-dependent heterogeneity in amyloid \u03b2 burden in autosomal dominant Alzheimer\u2019s disease: cross-sectional and longitudinal analyses of an observational study. Lancet Neurol. 21, 140\u2013152 (2022).","journal-title":"Lancet Neurol."},{"key":"34538_CR29","doi-asserted-by":"publisher","first-page":"954","DOI":"10.1038\/s41591-021-01382-x","volume":"27","author":"O Hansson","year":"2021","unstructured":"Hansson, O. Biomarkers for neurodegenerative diseases. Nat. Med. 27, 954\u2013963 (2021).","journal-title":"Nat. Med."},{"key":"34538_CR30","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1038\/nature09768","volume":"470","author":"MK Sandberg","year":"2011","unstructured":"Sandberg, M. K., Al-Doujaily, H., Sharps, B., Clarke, A. R. & Collinge, J. Prion propagation and toxicity in vivo occur in two distinct mechanistic phases. Nature 470, 540\u2013542 (2011).","journal-title":"Nature"},{"key":"34538_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/ncomms5347","volume":"5","author":"MK Sandberg","year":"2014","unstructured":"Sandberg, M. K. et al. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked. Nat. Commun. 5, 1\u20137 (2014).","journal-title":"Nat. Commun."},{"key":"34538_CR32","doi-asserted-by":"publisher","first-page":"6931","DOI":"10.1523\/JNEUROSCI.2262-14.2015","volume":"35","author":"DR Thakker","year":"2015","unstructured":"Thakker, D. R. et al. Centrally delivered BACE1 inhibitor activates microglia, and reverses amyloid pathology and cognitive deficit in aged Tg2576 mice. J. Neurosci. 35, 6931\u20136936 (2015).","journal-title":"J. Neurosci."},{"key":"34538_CR33","doi-asserted-by":"crossref","unstructured":"Eninger, T. et al. Signatures of glial activity can be detected in the CSF proteome. Proc. Natl. Acad. Sci. 119, e2119804119 (2022).","DOI":"10.1073\/pnas.2119804119"},{"key":"34538_CR34","doi-asserted-by":"publisher","first-page":"e11170","DOI":"10.15252\/emmm.201911170","volume":"11","author":"S Palmqvist","year":"2019","unstructured":"Palmqvist, S. et al. Cerebrospinal fluid and plasma biomarker trajectories with increasing amyloid deposition in Alzheimer\u2019s disease. EMBO Mol. Med. 11, e11170 (2019).","journal-title":"EMBO Mol. Med."},{"key":"34538_CR35","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1706441","volume":"378","author":"MF Egan","year":"2018","unstructured":"Egan, M. F. et al. Randomized trial of verubecestat for mild-to-moderate Alzheimer\u2019s disease. N. Engl. J. Med. 378, 1691\u20131703 (2018).","journal-title":"N. Engl. J. Med."},{"key":"34538_CR36","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1001\/jamaneurol.2019.3988","volume":"77","author":"AM Wessels","year":"2020","unstructured":"Wessels, A. M. et al. Efficacy and safety of lanabecestat for treatment of early and mild alzheimer disease: The AMARANTH and DAYBREAK-ALZ randomized clinical trials. JAMA Neurol. 77, 199\u2013209 (2020).","journal-title":"JAMA Neurol."},{"key":"34538_CR37","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.1038\/s41591-021-01369-8","volume":"27","author":"S Salloway","year":"2021","unstructured":"Salloway, S. et al. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer\u2019s disease. Nat. Med. 27, 1187\u20131196 (2021).","journal-title":"Nat. Med."},{"key":"34538_CR38","doi-asserted-by":"publisher","first-page":"e041143","DOI":"10.1002\/alz.041143","volume":"16","author":"M-L Rouzade-Dominguez","year":"2020","unstructured":"Rouzade-Dominguez, M.-L. et al. The API Generation program: Biomarker phenotyping of cognitively unimpaired participants screened in Generation study 1 and Generation study 2. Alzheimer\u2019s Dement 16, e041143 (2020).","journal-title":"Alzheimer\u2019s Dement"},{"key":"34538_CR39","doi-asserted-by":"publisher","unstructured":"Mintun, M. A. et al. Donanemab in Early Alzheimer\u2019s Disease. 384, https:\/\/doi.org\/10.1056\/NEJMoa2100708 1691\u20131704 (2021).","DOI":"10.1056\/NEJMoa2100708"},{"key":"34538_CR40","doi-asserted-by":"publisher","first-page":"e8462","DOI":"10.1126\/scitranslmed.aat8462","volume":"11","author":"A Aoyagi","year":"2019","unstructured":"Aoyagi, A. et al. A\u03b2 and tau prion-like activities decline with longevity in the Alzheimer\u2019s disease human brain. Sci. Transl. Med. 11, e8462 (2019).","journal-title":"Sci. Transl. Med."},{"key":"34538_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/2051-5960-2-30","volume":"2","author":"S Burgold","year":"2014","unstructured":"Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B. & Herms, J. In vivo imaging reveals sigmoidal growth kinetic of \u03b2-amyloid plaques. Acta Neuropathol. Commun. 2, 30 (2014).","journal-title":"Acta Neuropathol. Commun."},{"key":"34538_CR42","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1038\/nn.4117","volume":"18","author":"L Ye","year":"2015","unstructured":"Ye, L. et al. Persistence of A\u03b2 seeds in APP null mouse brain. Nat. Neurosci. 18, 1559\u20131561 (2015).","journal-title":"Nat. Neurosci."},{"key":"34538_CR43","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/nature20415","volume":"539","author":"J Collinge","year":"2016","unstructured":"Collinge, J. Mammalian prions and their wider relevance in neurodegenerative diseases. Nature 539, 217\u2013226 (2016).","journal-title":"Nature"},{"key":"34538_CR44","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1021\/cb4000376","volume":"8","author":"S Nystr\u00f6m","year":"2013","unstructured":"Nystr\u00f6m, S. et al. Evidence for age-dependent in vivo conformational rearrangement within A\u03b2 amyloid deposits. ACS Chem. Biol. 8, 1128\u20131133 (2013).","journal-title":"ACS Chem. Biol."},{"key":"34538_CR45","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1093\/brain\/awt362","volume":"137","author":"A Rijal Upadhaya","year":"2014","unstructured":"Rijal Upadhaya, A. et al. Biochemical stages of amyloid-\u03b2 peptide aggregation and accumulation in the human brain and their association with symptomatic and pathologically preclinical Alzheimer\u2019s disease. Brain 137, 887\u2013903 (2014).","journal-title":"Brain"},{"key":"34538_CR46","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/nm1782","volume":"14","author":"GM Shankar","year":"2008","unstructured":"Shankar, G. M. et al. Amyloid-\u03b2 protein dimers isolated directly from Alzheimer\u2019s brains impair synaptic plasticity and memory. Nat. Med. 14, 837\u2013842 (2008).","journal-title":"Nat. Med."},{"key":"34538_CR47","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/ana.23748","volume":"73","author":"TJ Esparza","year":"2013","unstructured":"Esparza, T. J. et al. Amyloid-\u03b2 oligomerization in Alzheimer dementia versus high-pathology controls. Ann. Neurol. 73, 104\u2013119 (2013).","journal-title":"Ann. Neurol."},{"key":"34538_CR48","doi-asserted-by":"publisher","first-page":"8667","DOI":"10.1039\/C8CC02204F","volume":"54","author":"M T\u00f6rnquist","year":"2018","unstructured":"T\u00f6rnquist, M. et al. Secondary nucleation in amyloid formation. Chem. Commun. 54, 8667\u20138684 (2018).","journal-title":"Chem. Commun."},{"key":"34538_CR49","doi-asserted-by":"crossref","unstructured":"Michaels, T. C. T., Dear, A. J., Cohen, S. I. A., Vendruscolo, M. & Knowles, T. P. J. Kinetic profiling of therapeutic strategies for inhibiting the formation of amyloid oligomers. J. Chem. Phys. 156, 164904 (2022).","DOI":"10.1063\/5.0077609"},{"key":"34538_CR50","first-page":"13287","volume":"94","author":"C Sturchler-Pierrat","year":"1997","unstructured":"Sturchler-Pierrat, C. et al. Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology. Neurobiology 94, 13287\u201313292 (1997).","journal-title":"Neurobiology"},{"key":"34538_CR51","doi-asserted-by":"publisher","unstructured":"He, Z. et al. Amyloid-\u03b2 plaques enhance Alzheimer\u2019s brain tau-seeded pathologies by facilitating neuritic plaque tau aggregation. Nat. Med., https:\/\/doi.org\/10.1038\/nm.4443 (2017).","DOI":"10.1038\/nm.4443"},{"key":"34538_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1038\/nature12481","volume":"501","author":"M Jucker","year":"2013","unstructured":"Jucker, M. & Walker, L. C. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases. Nature 501, 45\u201351 (2013).","journal-title":"Nature"},{"key":"34538_CR53","doi-asserted-by":"crossref","unstructured":"Joie, R. La et al. Prospective longitudinal atrophy in Alzheimer\u2019s disease correlates with the intensity and topography of baseline tau-PET. Sci. Transl. Med. 12, eaau5732 (2020).","DOI":"10.1126\/scitranslmed.aau5732"},{"key":"34538_CR54","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/S1474-4422(22)00027-8","volume":"21","author":"E Morenas-Rodr\u00edguez","year":"2022","unstructured":"Morenas-Rodr\u00edguez, E. et al. Soluble TREM2 in CSF and its association with other biomarkers and cognition in autosomal-dominant Alzheimer\u2019s disease: a longitudinal observational study. Lancet Neurol. 21, 329\u2013341 (2022).","journal-title":"Lancet Neurol."},{"key":"34538_CR55","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/S1474-4422(21)00361-6","volume":"21","author":"CE Teunissen","year":"2022","unstructured":"Teunissen, C. E. et al. Blood-based biomarkers for Alzheimer\u2019s disease: towards clinical implementation. Lancet Neurol. 21, 66\u201377 (2022).","journal-title":"Lancet Neurol."},{"key":"34538_CR56","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.cll.2020.04.002","volume":"40","author":"N Ferreira","year":"2020","unstructured":"Ferreira, N., do, C. & Caughey, B. Proteopathic seed amplification assays for neurodegenerative disorders. Clin. Lab. Med. 40, 257\u2013270 (2020).","journal-title":"Clin. Lab. Med."},{"key":"34538_CR57","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1186\/s13024-015-0033-8","volume":"10","author":"U Neumann","year":"2015","unstructured":"Neumann, U. et al. A novel BACE inhibitor NB-360 shows a superior pharmacological profile and robust reduction of amyloid-\u03b2 and neuroinflammation in APP transgenic mice. Mol. Neurodegener. 10, 44 (2015).","journal-title":"Mol. Neurodegener."},{"key":"34538_CR58","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1038\/s41593-020-00737-w","volume":"23","author":"RE Uhlmann","year":"2020","unstructured":"Uhlmann, R. E. et al. Acute targeting of pre-amyloid seeds in transgenic mice reduces Alzheimer-like pathology later in life. Nat. Neurosci. 23, 1580\u20131588 (2020).","journal-title":"Nat. Neurosci."},{"key":"34538_CR59","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s43587-021-00028-4","volume":"1","author":"SA Kaeser","year":"2021","unstructured":"Kaeser, S. A. et al. A neuronal blood marker is associated with mortality in old age. Nat. Aging 1, 218\u2013225 (2021).","journal-title":"Nat. Aging"},{"key":"34538_CR60","doi-asserted-by":"publisher","first-page":"194re2","DOI":"10.1126\/scitranslmed.3006446","volume":"5","author":"LF Maia","year":"2013","unstructured":"Maia, L. F. et al. Changes in amyloid- and tau in the cerebrospinal fluid of transgenic mice overexpressing amyloid precursor protein. Sci. Transl. Med. 5, 194re2 (2013).","journal-title":"Sci. Transl. Med."},{"key":"34538_CR61","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1126\/science.1194516","volume":"330","author":"YS Eisele","year":"2010","unstructured":"Eisele, Y. S. et al. Peripherally applied A\u03b2-containing inoculates induce cerebral \u03b2-amyloidosis. Science 330, 980\u2013982 (2010).","journal-title":"Science"},{"key":"34538_CR62","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1093\/oxfordjournals.aje.a118408","volume":"27","author":"LJ Reed","year":"1938","unstructured":"Reed, L. J. & Muench, H. A simple method of estimating fifty per cent endpoints. Am. J. Epidemiol. 27, 493\u2013497 (1938).","journal-title":"Am. J. Epidemiol."},{"key":"34538_CR63","first-page":"298","volume":"48","author":"P Armitage","year":"1950","unstructured":"Armitage, P. & Allen, I. Methods of estimating the LD 50 in quantal response data. Epidemiol. Infect. 48, 298\u2013322 (1950).","journal-title":"Epidemiol. Infect."},{"key":"34538_CR64","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1007\/BF01863914","volume":"162","author":"G K\u00e4rber","year":"1931","unstructured":"K\u00e4rber, G. Beitrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Naunyn-Schmiedebergs Arch f\u00fcr Exp Pathol und Pharmakologie 162, 480\u2013483 (1931).","journal-title":"Naunyn-Schmiedebergs Arch f\u00fcr Exp Pathol und Pharmakologie"},{"key":"34538_CR65","doi-asserted-by":"publisher","unstructured":"Dhandapani, R. et al. Sustained TREM2 stabilization accelerates microglia heterogeneity and A\u03b2 pathology in a mouse model of Alzheimer\u2019s disease. bioRxiv, https:\/\/doi.org\/10.1101\/2021.06.23.449405 (2021).","DOI":"10.1101\/2021.06.23.449405"},{"key":"34538_CR66","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13024-016-0134-z","volume":"11","author":"M Pigoni","year":"2016","unstructured":"Pigoni, M. et al. Seizure protein 6 and its homolog seizure 6-like protein are physiological substrates of BACE1 in neurons. Mol. Neurodegener. 11, 1\u201318 (2016).","journal-title":"Mol. Neurodegener."},{"key":"34538_CR67","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41592-019-0638-x","volume":"17","author":"V Demichev","year":"2020","unstructured":"Demichev, V., Messner, C. B., Vernardis, S. I., Lilley, K. S. & Ralser, M. DIA-NN: Neural networks and interference correction enable deep proteome coverage in high throughput. Nat. Methods 17, 41 (2020).","journal-title":"Nat. Methods"},{"key":"34538_CR68","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/nmeth.3901","volume":"13","author":"S Tyanova","year":"2016","unstructured":"Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731\u2013740 (2016).","journal-title":"Nat. Methods"},{"key":"34538_CR69","doi-asserted-by":"publisher","first-page":"D442","DOI":"10.1093\/nar\/gky1106","volume":"47","author":"Y Perez-Riverol","year":"2019","unstructured":"Perez-Riverol, Y. et al. The PRIDE database and related tools and resources in 2019: improving support for quantification data. Nucleic Acids Res. 47, D442\u2013D450 (2019).","journal-title":"Nucleic Acids Res."},{"key":"34538_CR70","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1016\/S1474-4422(18)30028-0","volume":"17","author":"BA Gordon","year":"2018","unstructured":"Gordon, B. A. et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer\u2019s disease: a longitudinal study. Lancet Neurol. 17, 241\u2013250 (2018).","journal-title":"Lancet Neurol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34538-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34538-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34538-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T18:40:40Z","timestamp":1669920040000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-022-34538-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,28]]},"references-count":70,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["34538"],"URL":"https:\/\/doi.org\/10.1038\/s41467-022-34538-5","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,28]]},"assertion":[{"value":"10 October 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"I.B., D.S., U.N. were employees of Novartis at the time the study was conducted. M.J. has received consulting fees from Papiling GmbH. All the other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"7333"}}